Genelux (GNLX) Operating Expenses (2022 - 2026)
Genelux (GNLX) posted Operating Expenses of $9.2 million for Q1 2026, down 2.64% on a QoQ basis from $9.4 million in Q4 2025, and up 17.34% year-over-year from $7.8 million in Q1 2025.
Analysis
Genelux (GNLX) Operating Expenses (2022 - 2026) Analysis & Trends
Genelux has reported Operating Expenses for 5 years, with the latest figure at $9.2 million in Q1 2026.
- On a quarterly basis, Operating Expenses rose 17.34% year-over-year to $9.2 million in Q1 2026; TTM through Mar 2026 was $34.6 million, a 10.13% increase from a year earlier, with the FY2025 full-year figure at $33.2 million, up 4.79% from the prior year.
- Operating Expenses was $9.2 million for Q1 2026 at Genelux, down from $9.4 million in the prior quarter.
- The five-year high for Operating Expenses was $9.7 million in Q4 2024, with the low at $3.2 million in Q4 2022.
- Average Operating Expenses over 5 years is $7.1 million, with a median of $7.0 million recorded in 2023.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses jumped 121.41% in 2023, then decreased 3.78% in 2025.
- Over 5 years, Operating Expenses stood at $3.2 million in 2022, then soared by 121.41% to $7.0 million in 2023, then soared by 39.24% to $9.7 million in 2024, then declined by 3.36% to $9.4 million in 2025, then slipped by 2.64% to $9.2 million in 2026.
- The last three Operating Expenses figures came in at $9.2 million (Q1 2026), $9.4 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 6.54 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 18.20 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 2.09 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 3.00 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -1.05 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 960.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.06 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 2.60 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 367.83 Mn |
| 10 | Genelux | 108.17 Mn | 108.17 Mn | - | 9.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 9.17 Mn |
| Dec 31, 2025 | 9.42 Mn |
| Sep 30, 2025 | 8.19 Mn |
| Jun 30, 2025 | 7.79 Mn |
| Mar 31, 2025 | 7.82 Mn |
| Dec 31, 2024 | 9.75 Mn |
| Sep 30, 2024 | 6.94 Mn |
| Jun 30, 2024 | 6.89 Mn |
| Mar 31, 2024 | 8.12 Mn |
| Dec 31, 2023 | 7.00 Mn |
| Sep 30, 2023 | 5.31 Mn |
| Jun 30, 2023 | 5.40 Mn |
| Mar 31, 2023 | 6.63 Mn |
| Dec 31, 2022 | 3.16 Mn |
| Sep 30, 2022 | 4.66 Mn |